Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapies and future directions in metastatic colorectal cancer

Chemotherapies and future directions in metastatic colorectal cancer Summary Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Chemotherapies and future directions in metastatic colorectal cancer

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/chemotherapies-and-future-directions-in-metastatic-colorectal-cancer-9yAfwHPhus
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0351-3
Publisher site
See Article on Publisher Site

Abstract

Summary Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • Cancer Statistics, 2017
    RL Siegel, KD Miller, A Jemal
  • Global cancer incidence and mortality rates and trends – an update
    LA Torre, RL Siegel, EM Ward, A Jemal
  • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis
    P Thirion, S Michiels, JP Pignon, M Buyse, AC Braud, RW Carlson
  • Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    RM Goldberg, DJ Sargent, RF Morton, CS Fuchs, RK Ramanathan, SK Williamson
  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
    C Tournigand, T Andre, E Achille, G Lledo, M Flesh, D Mery-Mignard
  • Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    J Cassidy, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong
  • Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
    A Falcone, S Ricci, I Brunetti, E Pfanner, G Allegrini, C Barbara
  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    V Heinemann, LF Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, SE Al-Batran
  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi
  • Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
    C Heidelberger, NK Chaudhuri, P Danneberg, D Mooren, L Griesbach, R Duschinsky
  • Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
    PM Wilson, PV Danenberg, PG Johnston, HJ Lenz, RD Ladner
  • Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies
    OH Temmink, T Emura, M Bruin, M Fukushima, GJ Peters
  • TAS-102, a novel antitumor agent: a review of the mechanism of action
    HJ Lenz, S Stintzing, F Loupakis
  • Randomized trial of TAS-102 for refractory metastatic colorectal cancer
    RJ Mayer, E Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, N Mizunuma
  • TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
    F Petrelli, S Barni, P Bertocchi, A Zaniboni
  • A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)
    H Bando, T Doi, K Muro, H Yasui, T Nishina, K Yamaguchi
  • Nanotechnologies for the treatment of colon cancer: From old drugs to new hope
    L Kotelevets, E Chastre, D Desmaele, P Couvreur
  • Efficacy of oxaliplatin in the treatment of colorectal cancer
    ML Rothenberg
  • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    A Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy
  • Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
    Y Kawato, M Aonuma, Y Hirota, H Kuga, K Sato
  • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    D Cunningham, S Pyrhonen, RD James, CJ Punt, TF Hickish, R Heikkila
  • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
    LB Saltz, JV Cox, C Blanke, LS Rosen, L Fehrenbacher, MJ Moore
  • The blood supply of neoplasms in the liver
    C Breedis, G Young
  • Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer
    N Kemeny, W Jarnagin, M Gonen, J Stockman, L Blumgart, D Sperber
  • Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
    NE Kemeny, D Niedzwiecki, DR Hollis, HJ Lenz, RS Warren, MJ Naughton
  • Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies
    A Cercek, TM Boucher, JS Gluskin, A Aguilo, JF Chou, LC Connell
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab
    A Cercek, M D’Angelica, D Power, M Capanu, A Gewirtz, D Patel
  • PD-1 blockade in tumors with mismatch-repair deficiency
    DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring
  • Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
    J Bendell, T Kim, B Goh, J Wallin, D Oh, S Han
  • Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016. https://doi.org/10.1001/jamaoncol.2016.3797
    Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer
  • Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)
    H-J Lenz
  • Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
    S Stintzing
  • Corcoran RB, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC). Ann Oncol. 2016; Abstract 455O
    Corcoran RB, et al. Efficacy and circulating tumor DNA
  • Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
    S Kopetz
  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
    A Sartore-Bianchi